公开(公告)号：US20250011292A1

公开(公告)日：2025-01-09

申请号：US18698251

申请日：2022-10-12

Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

Inventor： Binghe WANG ,  Xiaoxiao Yang ,  Ming Luo ,  Mukesh Kumar

IPC: C07D277/36 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/5377 ,  A61P31/14 ,  C07D417/06 ,  C07D417/14

Abstract: Novel rhodanine derivatives and methods for their use are provided herein. The rhodanine derivatives are useful in treating or preventing viral infections, including coronavirus infections (e.g., a SARS-CoV-2 virus infection). The rhodanine derivatives are also useful as photosensitizers for photodynamic therapy in treating or preventing cancer in a subject.

公开(公告)号：US12017975B2

公开(公告)日：2024-06-25

申请号：US17966227

申请日：2022-10-14

Applicant: THE UNIVERSITY OF BRITISH COLUMBIA

Inventor： Artem Tcherkassov ,  Paul S. Rennie ,  Fuqiang Ban ,  Eric J. J. Leblanc ,  Lavinia A. Carabet ,  Nada Lallous ,  Kriti Singh ,  Helene Morin ,  Anh-Tien Ton

IPC: C07C237/22 ,  C07C255/66 ,  C07C275/30 ,  C07C311/18 ,  C07C335/16 ,  C07C335/18 ,  C07D211/42 ,  C07D213/40 ,  C07D213/61 ,  C07D231/14 ,  C07D239/42 ,  C07D241/24 ,  C07D249/08 ,  C07D261/08 ,  C07D265/30 ,  C07D265/36 ,  C07D277/36 ,  C07D307/14 ,  C07D311/16 ,  C07D333/20 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07C237/22 ,  C07C255/66 ,  C07C275/30 ,  C07C311/18 ,  C07C335/16 ,  C07C335/18 ,  C07D211/42 ,  C07D213/40 ,  C07D213/61 ,  C07D231/14 ,  C07D239/42 ,  C07D241/24 ,  C07D249/08 ,  C07D261/08 ,  C07D265/30 ,  C07D265/36 ,  C07D277/36 ,  C07D307/14 ,  C07D311/16 ,  C07D333/20 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04

Abstract: Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

公开(公告)号：US11897853B2

公开(公告)日：2024-02-13

申请号：US17419417

申请日：2019-12-30

Applicant: ADAMA MAKHTESHIM LTD.

Inventor： Thomas Zell ,  Shlomi Cohen

IPC: C07D277/36 ,  B01J23/30

CPC classification number: C07D277/36 ,  B01J23/30

Abstract: The present invention provides a process for preparing a compound of formula [I] from a compound of formula [II] using an oxidizing agent and a catalyst, the process is carried out at a low temperature.

公开(公告)号：US20230317931A1

公开(公告)日：2023-10-05

申请号：US18303577

申请日：2023-04-20

Applicant: SK On Co., Ltd.

Inventor： Jik Soo KIM ,  Sang Bok KIM ,  Hyo Shin KWAK ,  Myoung Lae KIM ,  Se Rah MOON ,  Jin Seok SEO ,  Mi Jung NOH ,  Duck Chul HWANG

IPC: H01M4/36 ,  H01M4/525 ,  H01M10/0525 ,  H01M4/62 ,  C07D295/14 ,  C07D277/36

CPC classification number: H01M4/366 ,  C07D277/36 ,  C07D295/14 ,  H01M4/525 ,  H01M4/628 ,  H01M10/0525 ,  H01M2004/028

Abstract: A cathode active material for a lithium secondary battery includes a lithium metal oxide particle and a thio-based compound formed on at least portion of a surface of the lithium metal oxide particle. The thio-based compound has a double bond that contains a sulfur atom. Chemical stability of the lithium metal oxide particle may be improved and surface residues may be reduced by the thio-based compound.

公开(公告)号：US20220411392A1

公开(公告)日：2022-12-29

申请号：US17776513

申请日：2020-11-12

Applicant: Chengdu Baiyu Pharmaceutical Co., Ltd.

Inventor： Yonggang Wei ,  Hongzhu Chu ,  Yue Gao ,  Lingfeng Xiong ,  Guizhuan Su ,  Meiwei Wang ,  Yi Sun

IPC: C07D307/64 ,  C07D405/12 ,  C07D277/36 ,  C07D333/34 ,  C07D409/04

Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.

公开(公告)号：US20220387397A1

公开(公告)日：2022-12-08

申请号：US17287837

申请日：2019-10-23

Applicant: Novartis AG

Inventor： William ROUSH ,  Shankar VENKATRAMAN ,  Shomir GHOSH ,  Dong-Ming SHEN ,  Jason KATZ ,  Hans Martin SEIDEL

IPC: A61K31/426 ,  A61P29/00 ,  A61P1/00 ,  A61K45/06 ,  A61K39/395 ,  A61K31/341 ,  C07D307/64 ,  C07D277/36 ,  C07C311/51 ,  A61K31/18

Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20220356158A1

公开(公告)日：2022-11-10

申请号：US17191305

申请日：2021-03-03

Applicant: ImmuneSensor Therapeutics, Inc. ,  The Board of Regents of the University of Texas System

Inventor： Boyu ZHONG ,  Lijun SUN ,  Heping SHI ,  Jing LI ,  Chuo CHEN ,  Zhijian CHEN

IPC: C07D277/34 ,  C07D417/14 ,  A61K31/429 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/427 ,  C07D277/40 ,  A61K31/437 ,  A61K31/426 ,  A61K31/381 ,  A61K31/433 ,  A61K31/4709 ,  A61K39/39 ,  A61K45/06 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  C07D277/36 ,  C07D403/06 ,  C07D417/04 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

公开(公告)号：US11447460B2

公开(公告)日：2022-09-20

申请号：US16094487

申请日：2017-04-18

Applicant: Novartis AG

Inventor： Gary Glick ,  Shomir Ghosh ,  William R. Roush ,  Dong-Ming Shen

IPC: C07D333/34 ,  C07D215/36 ,  C07D265/30 ,  C07D213/28 ,  C07D307/64 ,  C07D231/44 ,  C07D277/34 ,  C07D307/82 ,  C07C381/00 ,  C07C311/29 ,  C07C317/14 ,  C07C311/37 ,  C07C311/51 ,  C07D231/18 ,  C07D277/36

Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20220267286A2

公开(公告)日：2022-08-25

申请号：US17405506

申请日：2021-08-18

Applicant: Rui Manuel Pontes Meireles Ferreira de Brito ,  Carlos José Vieira Simões ,  Teresa Margarida Vasconcelos Dias de Pinho e Melo ,  Bruno Lourenço da Silva Victor ,  Zaida Catarina Lourenço de Almeida ,  Ana Lúcia Cabral Cardoso Lopes ,  Bruno Filipe Oliveira Nascimento

Inventor： Rui Manuel Pontes Meireles Ferreira de Brito ,  Carlos José Vieira Simões ,  Teresa Margarida Vasconcelos Dias de Pinho e Melo ,  Bruno Lourenço da Silva Victor ,  Zaida Catarina Lourenço de Almeida ,  Ana Lúcia Cabral Cardoso Lopes ,  Bruno Filipe Oliveira Nascimento

IPC: C07D277/36 ,  C07D277/34 ,  A61K9/00 ,  A61K31/426 ,  A61K45/06

Abstract: Compounds are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).

公开(公告)号：US20220169682A1

公开(公告)日：2022-06-02

申请号：US17600329

申请日：2020-04-03

Applicant: PARIS SCIENCES ET LETTRES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  SORBONNE UNIVERSITÉ

Inventor： Arnaud GAUTIER ,  Alison TEBO

IPC: C07K14/195 ,  C07D277/36 ,  G01N33/58 ,  G01N33/68

Abstract: A complementation system including two fragments of photoactive yellow protein (PYP), or truncated fragments thereof, and its use with a fluorogenic hydroxybenzylidene rhodanine (HBR) analog for detecting interactions between biological molecules of interest, in particular between proteins of interest. Especially, a complementation system including a first PYP fragment having an amino acid sequence having at least about 70% identity with the amino acid sequence of SEQ ID NO: 23, or a truncated fragment thereof including at least 89 consecutive amino acids from the C-terminal end of the amino acid sequence; and a second PYP fragment having an amino acid sequence having at least about 70% identity with the amino acid sequence of SEQ ID NO: 34, or a truncated fragment thereof including at least 8 consecutive amino acids of the amino acid sequence, preferably 8 consecutive amino acids from the N-terminal end of the amino acid sequence.